See more : Meta Platforms, Inc. (META.NE) Income Statement Analysis – Financial Results
Complete financial analysis of Vivani Medical, Inc. (VANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivani Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- KFS (7743.TWO) Income Statement Analysis – Financial Results
- MCAP Inc. (MCAP) Income Statement Analysis – Financial Results
- WONIK Materials Co.,Ltd. (104830.KQ) Income Statement Analysis – Financial Results
- Hunan Valin Wire & Cable Co.,Ltd. (001208.SZ) Income Statement Analysis – Financial Results
- Solum Co., Ltd. (248070.KS) Income Statement Analysis – Financial Results
Vivani Medical, Inc. (VANI)
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 6.90M | 7.96M | 3.99M | 8.95M | 3.40M | 1.56M | 1.37M |
| Cost of Revenue | 357.00K | 381.00K | 345.00K | 167.00K | 2.15M | 4.89M | 7.75M | 9.35M | 4.30M | 3.56M | 5.63M | 4.40M |
| Gross Profit | -357.00K | -381.00K | -345.00K | -167.00K | 1.23M | 2.01M | 211.00K | -5.36M | 4.65M | -160.28K | -4.06M | -3.03M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 36.31% | 29.12% | 2.65% | -134.60% | 51.93% | -4.72% | -259.72% | -221.58% |
| Research & Development | 16.97M | 14.17M | 11.00M | 6.87M | 16.50M | 10.21M | 7.99M | 5.35M | 3.04M | 5.04M | 3.25M | 3.05M |
| General & Administrative | 10.00M | 7.07M | 2.32M | 2.38M | 9.23M | 10.69M | 10.93M | 10.08M | 8.22M | 6.57M | 4.17M | 4.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.10M | 11.34M | 9.57M | 8.99M | 8.94M | 6.84M | 3.30M | 2.19M |
| SG&A | 10.00M | 7.07M | 2.32M | 2.38M | 15.33M | 26.63M | 23.56M | 21.77M | 20.67M | 13.41M | 7.47M | 6.22M |
| Other Expenses | 0.00 | 475.00K | -91.00K | -36.00K | 3.35M | 4.60M | 2.64M | -727.00K | -991.00K | 2.62M | 3.22M | 3.73M |
| Operating Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 31.82M | 36.83M | 28.92M | 27.85M | 24.70M | 21.07M | 13.93M | 12.99M |
| Cost & Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 33.98M | 41.72M | 36.67M | 37.20M | 29.00M | 24.63M | 19.56M | 17.39M |
| Interest Income | 0.00 | 0.00 | 0.00 | 16.00K | 362.00K | 86.00K | 93.00K | 31.00K | 2.00K | 9.11K | 7.45K | 7.51K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 7.03M | 5.01M | 267.03K |
| Depreciation & Amortization | 357.00K | 381.00K | 345.00K | 167.00K | 414.00K | 435.00K | 457.00K | 432.00K | 335.00K | 279.18K | 315.77K | 324.71K |
| EBITDA | -26.61M | -19.16M | -12.98M | -8.89M | -33.18M | -34.66M | -28.06M | -32.75M | -19.68M | -27.89M | -17.64M | -15.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -893.25% | -498.69% | -354.75% | -822.53% | -220.25% | -820.75% | -1,127.18% | -1,147.39% |
| Operating Income | -26.97M | -21.24M | -13.32M | -9.24M | -30.60M | -34.83M | -28.71M | -33.21M | -20.05M | -21.23M | -18.00M | -16.02M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -905.50% | -505.00% | -360.48% | -833.38% | -223.99% | -624.91% | -1,150.05% | -1,171.82% |
| Total Other Income/Expenses | 1.31M | 7.35M | 550.00K | -36.00K | -3.00M | -269.00K | 193.00K | 31.00K | 29.00K | -13.97M | -4.97M | -257.74K |
| Income Before Tax | -25.65M | -13.89M | -12.77M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| Income Tax Expense | 0.00 | -7.35M | -641.00K | 147.70K | 362.00K | 86.00K | 93.00K | 31.00K | 58.00K | -6.93M | 42.22K | 9.29K |
| Net Income | -25.65M | -6.54M | -12.13M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| EPS | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| EPS Diluted | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| Weighted Avg Shares Out | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
| Weighted Avg Shares Out (Dil) | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?
Second Sight Medical Products Announces Closing of Public Offering
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of...
Second Sight Medical Products Announces Pricing of Public Offering
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of...
Second Sight Medical Products Announces Proposed Public Offering of Common Stock
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends...
3 Biotech Penny Stocks That Are Popular on Reddit Right Now
Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company...
EYES Stock: Over 30% Increase Intraday Explanation
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by over 30% during intraday trading. This is why it happened.
Why Second Sight Medical, Lucira Health, RA Medical Are Moving Today
Second Sight Medical Products, Inc. (NASDAQ: EYES), Lucira Health, Inc. (NASDAQ: LHDX) and Ra Medical Systems, Inc. (NYSE: RMED) were among the biggest health care gainers Wednesday. Second Sight Rallies On Positive Results For Visual Prosthesis: Second Sight, which makes...
What To Watch For As Second Sight Stock Gaps Higher On Vision Study Results
Second Sight Medical Products Inc. (NASDAQ: EYES) shares gapped up Wednesday morning following the two-year results from the company's Orion Study in visual prosthetics. Four out of five patients are able to better identify the direction of motion of a bar...
Source: https://incomestatements.info
Category: Stock Reports